D. Boral Capital Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective increased by D. Boral Capital from $2.00 to $3.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and a consensus target price of $5.00.

Lineage Cell Therapeutics Stock Up 0.5%

Shares of Lineage Cell Therapeutics stock traded up $0.01 during midday trading on Friday, hitting $1.85. The company had a trading volume of 1,688,224 shares, compared to its average volume of 1,080,784. The stock has a market cap of $426.11 million, a price-to-earnings ratio of -6.61 and a beta of 1.74. Lineage Cell Therapeutics has a 12-month low of $0.37 and a 12-month high of $2.09. The company has a fifty day simple moving average of $1.72 and a 200 day simple moving average of $1.65.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 74.10%. The business had revenue of $6.61 million during the quarter, compared to analysts’ expectations of $1.96 million. As a group, analysts expect that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in Lineage Cell Therapeutics during the 4th quarter valued at approximately $71,000. Jain Global LLC increased its stake in shares of Lineage Cell Therapeutics by 202.3% in the fourth quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after acquiring an additional 26,000 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth $303,000. Squarepoint Ops LLC purchased a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth $109,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth $473,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.